Depo-Medrone 40mg/ml with Lidocaine 10mg/ml Suspension for Injection, 2ml Vial

  • Name:

    Depo-Medrone 40mg/ml with Lidocaine 10mg/ml Suspension for Injection, 2ml Vial

  • Company:
    info
  • Active Ingredients:

    Lidocaine Hydrochloride, Methylprednisolone Acetate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 16/01/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 16/1/2020

Click on this link to Download PDF directly

Pfizer Healthcare Ireland

Pfizer Healthcare Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Accupro 10 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 20 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 40 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 5 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accuretic 20 mg/12.5 mg Tablets Active Ingredients Hydrochlorothiazide, Quinapril hydrochloride
Medicine Name Aciclovir 25 mg/ml Concentrate for Solution for Infusion. Active Ingredients Aciclovir sodium
Medicine Name Aldactone 100mg film coated tablets Active Ingredients Spironolactone
Medicine Name Aldactone 25mg film-coated tablets Active Ingredients Spironolactone
Medicine Name Aldactone 50 mg Film-coated tablets. Active Ingredients Spironolactone
Medicine Name Amlodipine Pfizer 10 mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Amlodipine Pfizer 5 mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Anugesic HC Cream Active Ingredients Balsam Peru, Benzyl Benzoate, Bismuth Oxide, Hydrocortisone Acetate, Pramocaine Hydrochloride, Zinc Oxide
Medicine Name ARICEPT 10 mg film coated tablets Active Ingredients Donepezil Hydrochloride
Medicine Name ARICEPT 5 mg film coated tablets Active Ingredients Donepezil Hydrochloride
Medicine Name Aromasin 25 mg coated tablets Active Ingredients Exemestane
Medicine Name Arthrotec 50 Active Ingredients Diclofenac Sodium, Misoprostol
Medicine Name Arthrotec 75 modified-release tablets Active Ingredients Diclofenac Sodium, Misoprostol
Medicine Name Ativan 1mg Tablets Active Ingredients Lorazepam
Medicine Name ATIVAN INJECTION Active Ingredients Lorazepam
Medicine Name BeneFIX Active Ingredients nonacog alfa
Medicine Name BESPONSA 1 mg powder for concentrate for solution for infusion Active Ingredients Inotuzumab ozogamicin
Medicine Name Bosulif 100 mg, 400 mg & 500 mg film-coated tablets Active Ingredients Bosutinib monohydrate
Medicine Name Cabaser 1mg Tablet Active Ingredients Cabergoline
Medicine Name Cabaser 2mg Tablet Active Ingredients Cabergoline
Medicine Name CAMPTO 20 mg/ml, concentrate for solution for infusion Active Ingredients Irinotecan hydrochloride trihydrate
1 - 0 of 227 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 16 January 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 16 January 2020 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following changes to the labelling have been approved. Please refer to attached copy/copies of labelling documentation for full details.

The SPC has been updated as follows: Sections 4.4 to add information about peritonitis; section 4.6 to add information on low birth weight, relationship to dose and impairment of fertility; 4.5 to remove a cautionary statement about the use of aspirin and corticosteroids in patients with hypoprothrombinemia; 4.8 to add peritonitis and anaphylactoid reaction as well as PT updates; 5.2 to add PK information pertaining to lidocaine; and 5.3 to add information concerning impairment of fertility, carcinogenesis, mutagenesis, embryo-foetal lethality, and details from animal studies. Changes in line with CDS.

Updated on 10 April 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 26 September 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:


IE DML 027 - CDS revised to align with the information across the corticosteroid CDSs

IE DML 029 - CDS revised to include a warning for Epidural lipomatosis & Central serous chorioretinopathy. Updates also regarding use of intrathecal/epidural routes of administration and to align with the information across the corticosteroid CDSs.

IE DML 031 - CDS was revised to include a warning for Pheochromocytoma.

IE DML 034 - CDS was updated to include warnings for benzyl alcohol and to separate information for methylprednisolone acetate and lidocaine throughout SPC

IE DML 037 – CDS was updated to add statement re discouraging use of high doses of corticosteroids to treat traumatic brain injury and impairment of fertility. Also to add information re pharmacokinetic properties and pre-clinical safety data.

IE DM 042 – CDS was updated to add warning concerning thrombosis including venous thromboembolism and to add thrombosis and pulmonary embolism as new ADRs. Also to remove the term ‘high doses’ from the statement regarding treatment of traumatic brain injury.

IE DM 047 – SPC was updated in line with PRAC updates: methylprednisolone PSUSA-00002026-201411. Update was included in IE DML 034 and 037 updates.

IE DML 053 - SPC was updated in line with PRAC updates: methylprednisolone PSUSA-00000449-201604

Updated on 29 August 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

IE DM 025 - CDS revised to align with the information across the corticosteroid CDSs, and to fulfil PSUR commitment (to update the SPC with reference to Kaposi’s Sarcoma and to reformat section 4.8 of the SPCs.)

IE DM 029 - CDS revised to align with the information across the corticosteroid CDSs.

IE DM 031 - CDS was revised to include a warning for Pheochromocytoma.

IE DM 033 - CDS was updated to include warnings for benzyl alcohol.

IE DM 036 – CDS was updated to add statement re discouraging use of high doses of corticosteroids to treat traumatic brain injury.

IE DM 037 – CDS was updated to add warning concerning thrombosis including venous thromboembolism and to add thrombosis and pulmonary embolism as new ADRs.

IE DM 042 – SPC was updated in line with PRAC updates: methylprednisolone PSUSA-00002026-201411

IE DM 048 - CDS was updated to add a cautionary statement about use in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.

IE DM 049 - SPC was updated in line with PRAC updates: methylprednisolone PSUSA-00000449-201604

Updated on 9 August 2018 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 3 - dose and frequency
  • Change to section 3 - duration of treatment
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 9 August 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

VAR II CDS update (s4.2, 4.3, 4.4, 5.4, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3); 2012-0001342

 

VAR II CDS update (s4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.2, 5.3); 2013-001977, 2013-0002862

 

VAR II CDS update (s4.4); 2013-0003195

 

VAR II CDS update (s4.2, 4.4, 4.6, 4.8, 4.9, 5.1, 5.2); 3013-0004235

 

VAR II CDS update (s4.4, 4.6, 5.2, 5.3); 2014-0005478, 2014-0005532, 2014-0005135

 

VAR II CDS update (s4.4, 4.8); 2014-0007607, 2014-0007608

 

VAR IB PRAC update (s4.4, 4.8); 2015-0013452

 

VAR II CDS update (s4.4, 4.8); 2018-0036511

Updated on 6 June 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.4 - Special warnings and precautions for use

Updated on 30 April 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

s4.4 Special warnings and precautions for use

Addition of a cautionary statement about use in patients with systemic sclerosis as increased incidence of scleroderma renal crisis observed with corticosteroids, including methylprednisolone

Updated on 26 April 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 5 April 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 April 2017 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 4 April 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 16 October 2012 PIL

Reasons for updating

  • Change of licence holder
  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 18 October 2011 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 10 August 2011 PIL

Reasons for updating

  • Change to date of revision
  • Correction of spelling/typing errors

Updated on 15 June 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 23 July 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 7 February 2007 PIL

Reasons for updating

  • Change from the BAN of the active substance to the rINN

Updated on 26 July 2006 PIL

Reasons for updating

  • New PIL for medicines.ie